POLE3 Antibody / CHRAC17

Overview

DNA replication is initiated by the binding of initiation factors to the origin of replication. Nucleosomes inhibit access to the replication machinery at these origin sequences. Nucleosome remodeling factors increase the accessibility of nucleosomal DNA to transcriptional regulators. CHRAC15 and CHRAC17 are subunits of the nucleosomal remodeling factor CHRAC (chromatin accessibility complex), which increases the accessibility of nucleosomal DNA in an ATP-dependent manner. Unlike other known chromatin remodeling factors, CHRAC also functions during chromatin assembly by using ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing. This conversion process occurs when CHRAC organizes randomly deposited histones into a regularly spaced array. In the presence of CHRAC, the nucleosomal ATPase ISWI catalyzes several ATP-dependent transitions of chromatin structure.

This anti-CHRAC17 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone PCRP-POLE3-2F10, Mouse IgG1, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: CHRAC17
• Format: Purified
• Localization: Nucleus, Cytoplasm
• Species reactivity: Human
• Applications (listed): FACS, IF, IHC-P
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone PCRP-POLE3-2F10, Mouse IgG1

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

CHRAC17 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling CHRAC17 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link CHRAC17 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• FACS
• IF
• IHC-P

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.